DDInter1534 DDInter1676
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Propafenone {u} (Compound) resembles {v} (Compound) Atomoxetine
Propafenone {u} (Compound) resembles {v} (Compound) Benazepril
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Propafenone {u} (Compound) binds {v} (Gene) CYP2C9
Propafenone {u} (Compound) upregulates {v} (Gene) KIAA0355
Propafenone {u} (Compound) downregulates {v} (Gene) IFRD2
Propafenone {u} (Compound) causes {v} (Side Effect) Lupus-like syndrome
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Propafenone (Compound) resembles Atomoxetine (Compound)
Propafenone (Compound) resembles Benazepril (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Propafenone (Compound) binds CYP2C9 (Gene)
Propafenone (Compound) upregulates KIAA0355 (Gene)
Propafenone (Compound) downregulates IFRD2 (Gene)
Propafenone (Compound) causes Lupus-like syndrome (Side Effect)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol